Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management
05/11/20, 11:03 AM
Location
menlo parkMoney raised
$65 million
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it has closed a $65 million convertible notes financing with a fund managed by Deerfield Management Company L.P. (“Deerfield”). The Company intends to use the proceeds from this financing for its commercial activities as well as general corporate purposes.
Company Info
Location
menlo park, california, united states
Additional Info
Intersect ENT is a company transforming care for patients with ear, nose and throat conditions. The Company’s steroid-releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.